Korean Biotech ETFs Plunge 20.63% in Past Month as U.S. Counterparts Hit New Highs

According to Maeil Business, Korean biotech exchange-traded funds diverged sharply from U.S. peers as of July 16. The TIGER Kosdaq 150 Biotech ETF fell 20.63% over the past month, while U.S. biotech indices climbed to 52-week highs. The SPDR S&P Biotech ETF (XBI) hit $165.71 on July 9. The correlation between Korean and U.S. biotech indices shifted from 0.55 through 2025 to -0.63 since Q2 2026, signaling a breakdown in their historical synchronization. Analysts attribute the divergence to concentrated capital flows toward Korean semiconductor leaders, while U.S. biotech benefits from sector rotation and large-cap pharma acquisitions of smaller biotech firms.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments